Broker Radar for February 19

Check out the stock commentaries and recommendations from brokerage houses.

Feb 19, 2019 02:02 IST India Infoline News Service

stock market
Macquarie maintained ‘Outperform’ on Nestle with a TP of Rs12,994
  • Management has indicated 24-36 new product launches in 2019.
  • Management expects greater acceleration in key brands growth in 2019. 
CLSA  upgraded Dr Reddy’s Laboratories to 'Buy' from ‘Outperform’ with a TP of Rs3,200
  • The US recovery and cost control are the key drivers for Dr. Reddy’s Laboratories.
BofAML maintained ‘Neutral’ on Ambuja Cement, raised TP to Rs255 from Rs233
  • December quarter missed estimates due to lower realisation and higher power and fuel cost.
  • Cost savings from lower fuel costs to realise in the first half of 2019.
  • Price decline in East and West led to decline in realisation.
Deutsche Bank maintained ‘Hold’ on Ambuja Cement with a TP of Rs220
  • December quarter disappointed again on weak margin.
  • Higher-than-industry cost inflation dents margin.
Citi maintained ‘Buy’ on Ambuja Cement with a TP of Rs480.
  • Proceeds should help pare debt at the group level due to stake sale.
  • Event reduces the overhang on the stock to some extent due to pledge concerns.
  • Promoters indicate that they don’t have any further stake sale.
(source: Media reports) 

Related Story